Alps Advisors Inc Y M Abs Therapeutics, Inc. Transaction History
Alps Advisors Inc
- $17.2 Billion
- Q1 2025
A detailed history of Alps Advisors Inc transactions in Y M Abs Therapeutics, Inc. stock. As of the latest transaction made, Alps Advisors Inc holds 33,309 shares of YMAB stock, worth $141,563. This represents 0.0% of its overall portfolio holdings.
Number of Shares
33,309
Previous 36,215
8.02%
Holding current value
$141,563
Previous $283,000
48.06%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding YMAB
# of Institutions
109Shares Held
26.6MCall Options Held
5.6KPut Options Held
900-
Paradigm Biocapital Advisors LP New York, NY4.24MShares$18 Million1.27% of portfolio
-
Black Rock Inc. New York, NY2.94MShares$12.5 Million0.0% of portfolio
-
Acorn Capital Advisors, LLC New York, NY2.86MShares$12.2 Million12.11% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA2.19MShares$9.33 Million1.4% of portfolio
-
Vanguard Group Inc Valley Forge, PA2MShares$8.5 Million0.0% of portfolio
About Y-mAbs Therapeutics, Inc.
- Ticker YMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,719,500
- Market Cap $186M
- Description
- Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...